Nesfatin-1与下丘脑性肥胖关系的研究进展
|
摘要
颅咽管瘤及其治疗会导致50%的患者出现下丘脑性肥胖,目前认为肥胖的形成主要与下丘脑损伤有关。Nesfatin-1作为一种新型饱腹因子,广泛地分布在中枢神经系统和外周组织中,尤其是在下丘脑、垂体、肝和脂肪组织中大量表达。近年研究显示Nesfatin-1在消化、内分泌、精神等多系统中发挥重要作用,但其作用机制尚未完全明确。本文综述了nesfatin-1的发现、结构、组织分布和调节能量代谢的环路,以期为下丘脑性肥胖的防控提供理论依据。
Craniopharyngioma and its treatment can cause hypothalamic obesity in 50% of patients.It is currently believed that the formation of obesity is mainly related to hypothalamic injury.As a novel satiety factor,Nesfatin-1 is widely distributed in the central nervous system and peripheral tissues, especially in the hypothalamus, pituitary, liver and adipose tissue. Recent studies have shown that nesfatin-l plays an important role in digestive, endocrine, and mental systems, but its mechanism of action has not been fully defined. This article reviews the discovery, structure, tissue distribution and regulation of energy metabolism in nesfatin-1,with the aim to provide theory evidence for hypothalamic obesity.
Craniopharyngioma and its treatment can cause hypothalamic obesity in 50% of patients.It is currently believed that the formation of obesity is mainly related to hypothalamic injury.As a novel satiety factor,Nesfatin-1 is widely distributed in the central nervous system and peripheral tissues, especially in the hypothalamus, pituitary, liver and adipose tissue. Recent studies have shown that nesfatin-l plays an important role in digestive, endocrine, and mental systems, but its mechanism of action has not been fully defined. This article reviews the discovery, structure, tissue distribution and regulation of energy metabolism in nesfatin-1,with the aim to provide theory evidence for hypothalamic obesity.
引文
[1]Oh.I S,Shimizu H,Satoh T,et al.Identification of nesfatin-1 as a satiety molecule in the hypothalamus[J].Nature,2006,443(7112):709-712.
[2]Shimizu H,Oh·I S,Hashimoto K,et al.Peripheral administralion of nesfatin-1 reduces food intake in mice:the leptin-independent mechanism[J].Endocrinology,2009,150(2):662-671.
[3]Muller HL,Bruhnken G,Emser A,et al.Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma.Childs Nerv Syst.2005;21(11):975-980.
[4]Olsson DS,Andersson E,Bryngelsson IL,Nilsson AG,Johannsson G.Excess mortality and morbidity in patients with craniopharyngioma,especially in patients with childhood onset:A population-based study in sweden.J Clin Endocrinol Metab.2015; 100(2):467-474.
[5]Wijnen M,Olsson DS,van den Heuvel-Eibrink MM,et al.Excess morbidity and mortality inpatients with craniopharyngioma:A hospital-based retrospective cohort study.Eur J Endocrinol.2018; 178(1):95-104.
[6]Erfurth EM.Endocrine aspects and sequel in patients with craniopharyngioma.[J].J Pediatr Endocrinol Metab.2015,28(1-2):19-26.
[7]Haliloglu B,Atay Z,Guran T,et al.Risk factors for mortality caused by hypothalamic obesity in children with hypothalamic tumours.Pediatr Obes.2016;11(5):383-388.
[8]Muller HL,Emser A,Faldum A,et al.Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab.2004;89(7):3298-3305.
[9]Cohen M,Guger S,Hamilton J.Long term sequelae of pediatric craniopharyngioma literature review and 20 years of experience.Front Endocrinol(Lausanne).2011;2:81.
[10]Sterkenburg AS,Hoffmann A,Gebhardt U,Warmuth-Metz M,Daubenbuchel AM, Muller HL.Survival,hypothalamic obesity,and neuropsychological/psychosocial status after childhood onset craniopharyngioma:Newly reported long-term outcomes.Neuro Oncol.2015; 17(7):1029-1038.
[2]Shimizu H,Oh·I S,Hashimoto K,et al.Peripheral administralion of nesfatin-1 reduces food intake in mice:the leptin-independent mechanism[J].Endocrinology,2009,150(2):662-671.
[3]Muller HL,Bruhnken G,Emser A,et al.Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma.Childs Nerv Syst.2005;21(11):975-980.
[4]Olsson DS,Andersson E,Bryngelsson IL,Nilsson AG,Johannsson G.Excess mortality and morbidity in patients with craniopharyngioma,especially in patients with childhood onset:A population-based study in sweden.J Clin Endocrinol Metab.2015; 100(2):467-474.
[5]Wijnen M,Olsson DS,van den Heuvel-Eibrink MM,et al.Excess morbidity and mortality inpatients with craniopharyngioma:A hospital-based retrospective cohort study.Eur J Endocrinol.2018; 178(1):95-104.
[6]Erfurth EM.Endocrine aspects and sequel in patients with craniopharyngioma.[J].J Pediatr Endocrinol Metab.2015,28(1-2):19-26.
[7]Haliloglu B,Atay Z,Guran T,et al.Risk factors for mortality caused by hypothalamic obesity in children with hypothalamic tumours.Pediatr Obes.2016;11(5):383-388.
[8]Muller HL,Emser A,Faldum A,et al.Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab.2004;89(7):3298-3305.
[9]Cohen M,Guger S,Hamilton J.Long term sequelae of pediatric craniopharyngioma literature review and 20 years of experience.Front Endocrinol(Lausanne).2011;2:81.
[10]Sterkenburg AS,Hoffmann A,Gebhardt U,Warmuth-Metz M,Daubenbuchel AM, Muller HL.Survival,hypothalamic obesity,and neuropsychological/psychosocial status after childhood onset craniopharyngioma:Newly reported long-term outcomes.Neuro Oncol.2015; 17(7):1029-1038.